Second Department of Hepatobiliary Surgery, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Department of Pathology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
J Exp Clin Cancer Res. 2019 Nov 21;38(1):473. doi: 10.1186/s13046-019-1475-6.
Circulating tumour cells (CTCs), especially mesenchymal CTCs, are important determinants of metastasis, which leads to most recurrence and mortality in hepatocellular carcinoma (HCC). However, little is known about the underlying mechanisms of CTC colonisation in pre-metastatic niches.
Detection and classification of CTCs in patients were performed using the CanPatrol™ system. A lentiviral vector expressing Prrx1-targeting shRNA was constructed to generate a stable HCC cell line with low expression of Prrx1. The effect of Prrx1 knockdown on stemness, migration, and drug resistance of the cell line was assessed, including involvement of SDF-1/CXCR4 signalling. Promising clinical applications of an inhibitor of STAT3 tyrosine phosphorylation, C188-9, and specific blockade with CXCR4 antibody were explored.
The number of mesenchymal CTCs in blood was closely associated with tumour recurrence or metastasis. Pre-metastatic niche-derived SDF-1 could downregulate Prrx1, which induced the stemness, drug resistance, and increased expression of CXCR4 in HCC cells through the STAT3 pathway in vitro. In vivo, mice bearing tumours of Prrx1 low-expressing cells had significantly shorter survival. In xenograft tumours and clinical samples, loss of Prrx1 was negatively correlated with increased expression of CXCR4 in lung metastatic sites compared with that in the primary foci.
These findings demonstrate that decreased expression of Prrx1 stimulates SDF-1/CXCR4 signalling and contributes to organ colonisation with blood CTCs in HCC. STAT3 inhibition and specific blockade of CXCR4 have clinical potential as therapeutics for eliminating organ metastasis in advanced HCC.
循环肿瘤细胞(CTC),特别是间充质 CTC,是转移的重要决定因素,导致肝细胞癌(HCC)中大多数复发和死亡。然而,关于 CTC 在转移前生态位中定植的潜在机制知之甚少。
使用 CanPatrol™系统检测和分类患者的 CTC。构建表达 Prrx1 靶向 shRNA 的慢病毒载体,以生成 Prrx1 低表达的稳定 HCC 细胞系。评估 Prrx1 敲低对细胞系干性、迁移和耐药性的影响,包括 SDF-1/CXCR4 信号的参与。探索 STAT3 酪氨酸磷酸化抑制剂 C188-9 和 CXCR4 抗体特异性阻断的有前途的临床应用。
血液中间充质 CTC 的数量与肿瘤复发或转移密切相关。前转移生态位衍生的 SDF-1 可以下调 Prrx1,这通过体外 STAT3 通路诱导 HCC 细胞的干性、耐药性和 CXCR4 的表达增加。在体内,表达 Prrx1 低的细胞系的荷瘤小鼠的生存时间明显缩短。在异种移植肿瘤和临床样本中,与原发性病灶相比,肺转移部位中 Prrx1 的缺失与 CXCR4 表达的增加呈负相关。
这些发现表明,Prrx1 表达的降低刺激 SDF-1/CXCR4 信号通路,并有助于 HCC 中血液 CTC 与器官的定植。STAT3 抑制和 CXCR4 的特异性阻断具有作为晚期 HCC 消除器官转移的治疗方法的临床潜力。